Business Description
Deciphera Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US24344T1016
Compare
Compare
Traded in other countries / regions
DCPH.USAD05.Germany IPO Date
2017-09-28Description
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.95 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.91 | |||||
| Beneish M-Score | -1.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 44.9 | |||||
| 3-Year EBITDA Growth Rate | 18.9 | |||||
| 3-Year EPS without NRI Growth Rate | 19.1 | |||||
| 3-Year FCF Growth Rate | 17.3 | |||||
| 3-Year Book Growth Rate | -21.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 21.41 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.29 | |||||
| 9-Day RSI | 36.83 | |||||
| 14-Day RSI | 39.23 | |||||
| 6-1 Month Momentum % | -3.93 | |||||
| 12-1 Month Momentum % | -20.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5 | |||||
| Quick Ratio | 4.69 | |||||
| Cash Ratio | 4.06 | |||||
| Days Inventory | 1122.19 | |||||
| Days Sales Outstanding | 59.38 | |||||
| Days Payable | 861.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.4 | |||||
| Shareholder Yield % | 0.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.97 | |||||
| Operating Margin % | -137.49 | |||||
| Net Margin % | -129.9 | |||||
| ROE % | -47.62 | |||||
| ROA % | -37.49 | |||||
| ROIC % | -209.85 | |||||
| ROC (Joel Greenblatt) % | -457.29 | |||||
| ROCE % | -47.29 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.15 | |||||
| PB Ratio | 2.42 | |||||
| Price-to-Tangible-Book | 2.42 | |||||
| EV-to-EBIT | -3.53 | |||||
| EV-to-EBITDA | -3.57 | |||||
| EV-to-Revenue | 4.85 | |||||
| EV-to-Forward-Revenue | 4.07 | |||||
| EV-to-FCF | -4.93 | |||||
| Price-to-Net-Current-Asset-Value | 3.27 | |||||
| Price-to-Net-Cash | 4.39 | |||||
| Earnings Yield (Greenblatt) % | -28.33 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DCPH
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Deciphera Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 144.068 | ||
| EPS (TTM) ($) | -2.32 | ||
| Beta | -0.38 | ||
| Volatility % | 28.88 | ||
| 14-Day RSI | 39.23 | ||
| 14-Day ATR ($) | 0.525998 | ||
| 20-Day SMA ($) | 13.5735 | ||
| 12-1 Month Momentum % | -20.65 | ||
| 52-Week Range ($) | 12.33 - 22.76 | ||
| Shares Outstanding (Mil) | 78.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Deciphera Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Deciphera Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Deciphera Pharmaceuticals Inc Frequently Asked Questions
What is Deciphera Pharmaceuticals Inc(DCPH)'s stock price today?
The current price of DCPH is $12.43. The 52 week high of DCPH is $22.76 and 52 week low is $12.33.
When is next earnings date of Deciphera Pharmaceuticals Inc(DCPH)?
The next earnings date of Deciphera Pharmaceuticals Inc(DCPH) is 2023-11-03 Est..
Does Deciphera Pharmaceuticals Inc(DCPH) pay dividends? If so, how much?
Deciphera Pharmaceuticals Inc(DCPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers